Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?

Yen, Fu-Shun; Lai, Jung-Nien; Wei, James Cheng-Chung; Chiu, Lu-Ting; Hsu, Chih-Cheng; Hou, Ming-Chih; Hwu, Chii-Min

doi:10.1186/s12876-021-01773-x

BMC Gastroenterology

Table 1 Baseline characteristics of insulin users and nonusers with diabetes and compensated liver cirrhosis

From: Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?

Variables	Before propensity score match					After propensity score match
	Non-insulin users (n = 17,173)		Insulin users (n = 2047)		p value	Non-insulin users (n = 4094)		Insulin users (n = 2047)		p value
	N	%	N	%	p value	n	%	n	%	p value
Age					0.01					0.54
18–49	5886	34.27	732	35.76		1444	35.27	732	35.76
50–65	7301	42.51	900	43.97		1793	43.80	900	43.97
> 65	3986	23.22	415	20.27		857	20.93	415	20.27
Mean ± SD	55.37 ± 11.91		54.98 ± 11.32		0.15	55.20 ± 11.82		54.98 ± 11.32		0.29
Sex					0.11					0.62
Female	5421	31.57	611	29.85		1197	29.24	611	29.85
Male	11,752	68.43	1436	70.15		2897	70.76	1436	70.15
DM age, mean ± SD	55.96 ± 11.12		51.93 ± 10.93		< 0.0001	52.58 ± 11.03		51.93 ± 10.93		0.06
DM duration, mean ± SD^a	4.85 ± 3.47		3.05 ± 2.79		< 0.0001	3.21 ± 3.94		3.05 ± 2.79		0.10
Antihypertensive drugs
ACEI/ARB	7401	43.10	1076	52.56	< 0.0001	2143	52.34	1076	52.56	0.87
β-blockers	9004	52.43	1298	63.41	< 0.0001	2567	62.70	1298	63.41	0.59
Calcium-channel blockers	5086	29.62	777	37.96	< 0.0001	1495	36.52	777	37.96	0.27
Diuretics	4304	25.06	699	34.15	< 0.0001	1384	33.81	699	34.15	0.79
Other anti-hypertensive agent	3350	19.51	521	25.45	< 0.0001	1034	25.26	521	25.45	0.87
Antidiabetic drugs
Metformin	5437	31.66	1033	50.46	< 0.0001	2036	49.73	1033	50.46	0.59
Sulfonylurea	6446	37.54	1178	57.55	< 0.0001	2337	57.08	1178	57.55	0.73
Meglitinide	1814	10.56	327	15.97	< 0.0001	644	15.73	327	15.97	0.80
Thiazolidinedione	2050	11.94	429	20.96	< 0.0001	789	19.27	429	20.96	0.12
α-glucosidase inhibitor	1779	10.36	341	16.66	< 0.0001	644	15.73	341	16.66	0.35
DPP-4 inhibitors	457	2.66	92	4.49	< 0.0001	199	4.86	92	4.49	0.53
Other drugs
Statin	4202	24.47	661	32.29	< 0.0001	1299	31.73	661	32.29	0.66
Aspirin	9556	55.65	1354	66.15	< 0.0001	2762	67.46	1354	66.15	0.30
DCSI score					< 0.0001					0.59
0	9298	54.14	732	35.76		1418	34.64	732	35.76
1	2595	15.11	397	19.39		786	19.20	397	19.39
≥ 2	5280	30.75	918	44.85		1890	46.17	918	44.85
CCI					< 0.0001					0.64
0	11,657	67.88	694	33.90		1357	33.15	694	33.90
1	2326	13.54	528	25.79		1101	26.89	528	25.79
≥ 2	3190	18.58	825	40.31	< 0.0001	1636	39.96	825	40.30
HBV	2810	16.36	491	23.99	< 0.0001	928	22.67	491	23.99	0.25
HCV	2093	12.19	407	19.88	< 0.0001	804	19.64	407	19.88	0.82

SD, standard deviation; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity index; DCSI score, diabetes complications severity index score; HBV, hepatitis B virus; HCV, hepatitis C virus
^at-test

Back to article page

ISSN: 1471-230X

Contact us

Submission enquiries: bmcgastroenterology@biomedcentral.com
General enquiries: ORSupport@springernature.com